Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

APLS : 27.40 (-0.33%)
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share...

FOLD : 9.52 (-0.73%)
AVIR : 3.21 (+1.58%)
CRSP : 45.99 (-2.69%)
APLS : 27.40 (-0.33%)
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday

Sales of the company's top commercialized product didn't meet expectations.

$SPX : 5,962.38 (+0.77%)
APLS : 27.40 (-0.33%)
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

APLS : 27.40 (-0.33%)
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst

It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.

BAC : 46.74 (+1.48%)
ALPMY : 10.1400 (+0.70%)
APLS : 27.40 (-0.33%)
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

APLS : 27.40 (-0.33%)
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

APLS : 27.40 (-0.33%)
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

APLS : 27.40 (-0.33%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

APLS : 27.40 (-0.33%)
Stocks Settle Mostly Lower on Chip Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) Friday closed down by -0.19%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.24%. Stocks...

AMAT : 176.56 (+3.80%)
FRO : 19.52 (-3.65%)
ADI : 214.27 (+1.54%)
TXN : 198.58 (+0.20%)
$IUXX : 20,786.53 (+0.58%)
ASML : 671.62 (+2.00%)
ZNZ24 : 109-170 (-0.14%)
GFS : 42.22 (+1.34%)
QCOM : 156.25 (+1.28%)
PBF : 32.39 (+2.40%)
VLO : 141.95 (+0.53%)
UPS : 131.17 (-0.70%)

Barchart Exclusives

Are Cattle Prices Heading for Record Highs in 2025?
Live and cattle feeder futures prices have risen since the 2020 pandemic-inspired lows. After reaching record highs in 2024, cattle futures are consolidating, and new highs could be on the horizon in 2025. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar